BUY
₹2,050
₹1,883.75
₹2,400
17.07%
Emkay Research, in its November 15, 2026 result update on Avalon Technologies, retained its BUY recommendation and DCF-based target price of Rs 2,400. The broker views the company’s fundamentals as strong following a robust 2QFY27 performance and considers its growth prospects favourable, although it notes that the share price had already risen around 132 per cent year to date.
The unchanged target price implies FY28E and FY29E P/E multiples of 60x and 41x, respectively.
Avalon Technologies reported operating revenue growth of 37.4 per cent YoY in 2QFY27, materially ahead of consensus expectations for 3.4 per cent growth. EBITDAM was 12.6 per cent against consensus expectations of 11.8 per cent, while the order book increased 27 per cent YoY.
Emkay highlights that this growth was achieved without scaled-up contributions from the SME, Kavach or HVDC programmes. The broker expects weakness in the automotive and medical verticals to reverse. Implied book-to-bill improved to 1.34 in 2QFY27 from 1.05 in 1QFY27 and 1.22 in 2QFY26, which Emkay believes supports the continuity of Avalon Technologies’ growth trajectory.
Management raised its FY27 revenue-growth guidance to around 30 per cent from the earlier 26-30 per cent range. Emkay describes this guidance as conservative, as it implies around 20 per cent YoY growth in 2HFY27. The broker considers a sharp deceleration across several verticals necessary for Avalon Technologies not to exceed this guidance, which it views as a lower-probability outcome.
Management said revenue should not be lumpy and that customers have not front-loaded orders. It also indicated that operating leverage behind the strong EBITDAM provides scope for further margin improvement.
Management sees a healthy semiconductor pipeline, with one customer potentially taking the semiconductor business to 10 per cent of total revenue in the near to medium term. Additional semiconductor revenue depends on winning other customers.
Management said a data centre or AI slowdown should not affect the order book because customers have visibility for the next few years and demand is supported by the global diversification of semiconductor capacity.
Emkay views the Zollner joint venture as a strategic accelerator because it can bring new European OEM customers and expand Avalon Technologies into medical and test-and-measurement equipment. The company has also signed a memorandum of understanding with the Tamil Nadu government for 25 acres of land for future expansion, involving Rs 530-540 million of land-acquisition capex.
Management reported asset turns of 10.7x and ROCE of 24.2 per cent. The broker also considers the balance sheet well capitalised after the warrants issue to Zollner.
Following 1HFY27 performance, Emkay fine-tuned and rolled forward its estimates.
| Metric | FY27E | Change vs earlier estimate | FY28E | Change vs earlier estimate | FY29E | Change vs earlier estimate |
|---|---|---|---|---|---|---|
| Revenue (Rs million) | 22,136 | -5.3 per cent | 32,492 | -4.3 per cent | 46,073 | -4.3 per cent |
| EBITDA (Rs million) | 2,810 | +0.8 per cent | Not specified | -3.4 per cent | Not specified | -7.7 per cent |
| EPS (Rs) | 25.38 | +1.3 per cent | Not specified | -3.7 per cent | Not specified | -8.7 per cent |
Key factors to monitor include the recovery in automotive and medical, execution of new programmes, conversion of the semiconductor pipeline, and the timing of revenue contribution from the Zollner joint venture during its facility-construction phase.
Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.
Copyright 2026 by DSIJ Wealth Advisory Pvt. Ltd. (Formerly Known as DSIJ Pvt. Ltd.)